Novartis has reported earlier successes with related mTOR compounds. In September the company presented the final results of a Phase III trial of Afinitor (everolimus) in patients with well-differentiated advanced and progressive pancreatic neuroendocrine tumors (pNET). This was part of the RADIANT-3 (RAD001 In Advanced Neuroendocrine Tumors) trial. mTOR (mammalian target of rapamycin) inhibition was confirmed in advanced pNET. The results of the study indicated a median overall survival (OS) of 44.02 months in patients receiving everolimus, compared to 37.68 months in those receiving placebo.
“Novartis has more than 25 years of helping to advance NET care and this study, part of the largest global clinical program in NET, emphasizes our commitment to helping fulfill unmet needs for patients living with this disease,” said Alessandro Riva, Global Head, Novartis Oncology Development and Medical Affairs in a statement.
“Novartis has more than 25 years of helping to advance NET care and this study, part of the largest global clinical program in NET, emphasizes our commitment to helping fulfill unmet needs for patients living with this disease,” said Alessandro Riva, Global Head, Novartis Oncology Development and Medical Affairs in a statement.
Novartis uber alles - you are warned
Aucun commentaire:
Enregistrer un commentaire